Literature DB >> 20166149

First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction.

Yan Zhong1, Methodius Tuuli, Anthony O Odibo.   

Abstract

Preeclampsia and intrauterine growth restriction (IUGR) are major contributors to perinatal mortality and morbidity worldwide. Both are characterized by impaired trophoblastic invasion of the maternal spiral arteries and their conversion from narrow muscular vessels to wide non-muscular channels. Despite improvement in the understanding of the pathophysiology of these conditions, ability to accurately identify pregnant woman who will develop them is limited. This greatly impairs the development and testing of preventive interventions. While different measures of placental dysfunction have been associated with increased risk for adverse pregnancy outcomes, the ability of any single one to accurately predict these outcomes is poor. Developing predictive tests is further challenged by difficulty in the timing of the measurements, as both the structural and biochemical characteristics of the placenta change with increasing gestational age. The ideal screening test would accurately predict the development of adverse pregnancy outcomes early enough to provide a window for preventive interventions. Improvement in ultrasound technology provides potentially useful novel tools for evaluating placental structure, but measurements need to be standardized in order to be useful. Maternal serum analyte screening is a noninvasive test of placental biochemical function, but present serum marker alone is not sufficiently accurate to suggest its routine use in clinical practice. The use of first trimester biochemical markers in combination with uterine artery Doppler screening is promising as a potential screening tool. Prospective longitudinal studies using standardized methodology are necessary to further evaluate the choice of parameters and strategies of combination to achieve the best predictive models. Copyright (c) 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20166149     DOI: 10.1002/pd.2475

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  30 in total

1.  Management of abnormal serum markers in the absence of aneuploidy or neural tube defects.

Authors:  William T Schnettler; Michele R Hacker; Rachel E Barber; Sarosh Rana
Journal:  J Matern Fetal Neonatal Med       Date:  2012-03-26

2.  A description of the methods of the Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b).

Authors:  David M Haas; Corette B Parker; Deborah A Wing; Samuel Parry; William A Grobman; Brian M Mercer; Hyagriv N Simhan; Matthew K Hoffman; Robert M Silver; Pathik Wadhwa; Jay D Iams; Matthew A Koch; Steve N Caritis; Ronald J Wapner; M Sean Esplin; Michal A Elovitz; Tatiana Foroud; Alan M Peaceman; George R Saade; Marian Willinger; Uma M Reddy
Journal:  Am J Obstet Gynecol       Date:  2015-01-31       Impact factor: 8.661

3.  Predictive accuracy of the first trimester Doppler scan: a meta-study.

Authors:  Naira Roland Matevosyan
Journal:  Wien Med Wochenschr       Date:  2015-06-16

4.  First-trimester levels of pregnancy-associated plasma protein A2 (PAPP-A2) in the maternal circulation are elevated in pregnancies that subsequently develop preeclampsia.

Authors:  Erin J Crosley; Ursula Durland; Ken Seethram; Scott MacRae; Andrée Gruslin; Julian K Christians
Journal:  Reprod Sci       Date:  2013-12-13       Impact factor: 3.060

5.  First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study.

Authors:  Anthony O Odibo; Katherine R Goetzinger; Linda Odibo; Alison G Cahill; George A Macones; D Michael Nelson; Dennis J Dietzen
Journal:  Prenat Diagn       Date:  2011-07-11       Impact factor: 3.050

6.  Fetal sex-related dysregulation in testosterone production and their receptor expression in the human placenta with preeclampsia.

Authors:  K Sathishkumar; M Balakrishnan; V Chinnathambi; M Chauhan; G D V Hankins; C Yallampalli
Journal:  J Perinatol       Date:  2011-09-08       Impact factor: 2.521

7.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

8.  Associations between ambient air pollution and Hypertensive Disorders of Pregnancy.

Authors:  Zahra Mobasher; Muhammad T Salam; T Murphy Goodwin; Frederick Lurmann; Sue A Ingles; Melissa L Wilson
Journal:  Environ Res       Date:  2013-03-21       Impact factor: 6.498

9.  Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy.

Authors:  Eleftheria Lefkou; Apostolos Mamopoulos; Themistoklis Dagklis; Christos Vosnakis; David Rousso; Guillermina Girardi
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

10.  Prediction of adverse pregnancy outcomes by extreme values of first trimester screening markers.

Authors:  Marina S Gomes; Mariana Carlos-Alves; Vera Trocado; Diana Arteiro; Paula Pinheiro
Journal:  Obstet Med       Date:  2017-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.